ReviewMedical hypothesis, discovery & innovation ophthalmology journal2024
A review on retinopathy of prematurity.
Review in Medical hypothesis, discovery & innovation ophthalmology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Clinical Performance and Implementation of AI-Enabled Paediatric Ophthalmic Screening, Triage, Diagnosis, and Surveillance in Primary, Community, and Referral-Linked Pathways: A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Machine learning-based individualized prediction: risk assessment of retinopathy in preterm infants at high altitude.BMC ophthalmology · 2026Article
- Retinopathy of prematurity: Clinical profiles and risk factors.Bioinformation · 2026Article
- Pericytes as key mediators of microenvironmental signaling crosstalk: implications in vascular diseases and cancer.Frontiers in cell and developmental biology · 2026Review
- Identification of risk factors of cystic periventricular leukomalacia in preterm infants.Frontiers in pediatrics · 2026Article
- Atypical p38 Kinase Signaling in Retinal Vascular Damage and Recovery.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Systematic review and meta-analysis of risk prediction models for retinopathy of prematurity in preterm infants.Biomedical reports · 2025Article
- From Blood Count Parameters to ROP Risk: Early Hematological Predictors in Preterm Infants.Medicina (Kaunas, Lithuania) · 2025Article
- Multiple Hub Genes as Diagnostic and Therapeutic Targets Inducing Inflammation and Angiogenesis in Retinopathy of Prematurity.International journal of general medicine · 2025Article
- Neonatal retinal hemorrhage and retinopathy of prematurity: a critical review of current practices and future directions.Therapeutic advances in ophthalmologyReview
- Study on the Role of Short Peptide LCKLSL Targeting ANXA2 in Retinal Neovascularization.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retinopathy of prematurity (ROP) is a leading cause of childhood blindness. It predominantly affects preterm infants with very low birth weights or extreme prematurity. Aberrant retinal vascular development, driven by hyperoxia and hypoxia-induced neovascularization, is central to ROP pathogenesis. This review explores the relationship between maternal health and ROP, evaluates current prevention strategies, assesses innovations in diagnostic and screening technologies, reviews contemporary treatments, and identifies future research directions. Methods: A literature review was conducted in the PubMed / MEDLINE, Scopus, Web of Science, and Google Scholar databases using related keywords, i.e., "retinopathy of prematurity," "retinal development," "pathophysiology," "vascular growth," "complications," "visual outcomes," "maternal health factors," "obstetrics," "preeclampsia," "risk factors," "preterm birth," "corticosteroids," "oxygen management," "treatment strategies," "laser therapy," "anti-VEGF agents," "surgical approaches", and "artificial intelligence (AI)" and targeting English studies published in the last 20 years. Additionally, the references from the selected articles were manually reviewed. Clinical trials, meta-analyses, systematic reviews, case-control studies, case series, narrative reviews, pilot studies, and relevant animal studies were included. Results: Maternal factors, such as diabetes, smoking, and preeclampsia, along with neonatal factors, such as low gestational age and extreme prematurity, are critical contributors to ROP. Key preventative strategies to reduce the risk of ROP and improve neonatal outcomes include: 1. prenatal care involves screening and managing maternal conditions, providing maternal education, and administering antenatal corticosteroids. 2. Neonatal care encompasses nutritional support, supplementation with essential fatty acids, and regulated oxygen administration. By focusing on these strategies, we can enhance the health of newborns at risk for ROP. Advances in screening, including artificial intelligence (AI)-assisted diagnostics and advanced imaging, are improving early detection. Treatment modalities such as laser photocoagulation, cryotherapy, and anti-vascular endothelial growth factor therapies have shown promise but pose challenges, including recurrence risk and systemic side effects. Conclusions: ROP continues to pose a major threat to the vision of preterm infants, particularly in regions with limited healthcare resources. Addressing ROP requires multidisciplinary team approaches that integrate obstetric and neonatal care. Preventative strategies, including prenatal care optimization, oxygen management, and nutritional support, are essential. Future efforts should focus on integrating emerging technologies and recent findings to ensure global relevance and currency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.